Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
FMO3	rs2266782	AA	sulindac	metabolism/PK	yes	Measures of exposure were AUC, Cmax, Tmax, and T1/2.	Genotype AA is associated with increased exposure to sulindac in healthy individuals as compared to genotype GG.	28331852	1448613020
FMO3	rs2266780	GG	sulindac	metabolism/PK	yes	Measures of exposure were AUC, Cmax, Tmax, and T1/2.	Genotype GG is associated with increased exposure to sulindac in healthy individuals as compared to genotype AA.	28331852	1448613027
FMO3	rs2266782	AA + AG	nicotine	metabolism/PK	no	This was described as a trend towards higher nicotine AUC. Participants received 4 mg oral nicotine.	Genotypes AA + AG is associated with decreased metabolism of nicotine in CYP2A6 reduced, but not normal, metabolizers as compared to genotype GG.	24448396	1183703319
FMO3	rs2266780	AA	nicotine	metabolism/PK	yes	Individuals with the AA genotype have a greater percent of both deuterated nicotine and non-deuterated nicotine metabolized to nicotine-N-oxide as compared to the AG or GG genotype.	Genotype AA is associated with increased metabolism of nicotine as compared to genotypes AG + GG.	28290528	1449157859
FMO3	rs2266782	G	cotinine	metabolism/PK	no	This SNP is not associated with the pharmacokinetic measures of cotinine. Measures include half-life, Cmax, AUC, non renal clearance, and total clearance.	Allele G is not associated with metabolism of cotinine in people with Tobacco Use Disorder as compared to allele A.	28178031	1448602091
FMO3	rs2266782	G	nicotine	metabolism/PK	no	This SNP is not associated with the pharmacokinetic measures of nicotine. Measures include half-life, Cmax, AUC, non renal clearance, and total clearance.	Allele G is not associated with metabolism of nicotine in people with Tobacco Use Disorder as compared to allele A.	28178031	1448602097
FMO3	rs2266782	AA	itopride	metabolism/PK	yes	The authors compared metabolism of itopride between 6 healthy volunteers with the GG genotype at rs2266782 and AA genotype at rs2266780 VERSUS 6 healthy volunteers with the AA genotype at rs2266782 and GG genotype at rs2266780. Several PK measurements were taken after a single dose of itopride including AUC of itopride and N-oxide itopride, Cmax of itopride and N-oxide itopride, as well as Tmax and half life of itopride. Only AUC and Cmax differed significantly between the two groups.	Genotype AA is associated with decreased metabolism of itopride in healthy individuals as compared to genotype GG.	25224784	1184755585
FMO3	rs2266780	GG	itopride	metabolism/PK	yes	The authors compared metabolism of itopride between 6 healthy volunteers with the GG genotype at rs2266782 and AA genotype at rs2266780 VERSUS 6 healthy volunteers with the AA genotype at rs2266782 and GG genotype at rs2266780. Several PK measurements were taken after a single dose of itopride including AUC of itopride and N-oxide itopride, Cmax of itopride and N-oxide itopride, as well as Tmax and half life of itopride. Only AUC and Cmax differed significantly between the two groups.	Genotype GG is associated with decreased metabolism of itopride in healthy individuals as compared to genotype AA.	25224784	1184755593
FMO3	rs1800822	CC	tacrolimus	metabolism/PK	yes	for donor genotype. Significant at weeks 2, 3, 4 and 1 month.	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	28084894	1448569520
FMO3	rs909530	CC	tacrolimus	metabolism/PK	yes	for donor genotype. Significant at weeks 2, 3 and 1 month.	Genotype CC is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CT + TT.	28084894	1448569532
FMO3	FMO3 haplotype		olanzapine	metabolism/PK	no	no PMs were present. Disease is not specified explicitly but study subjects are referred to as patients and the introduction discusses use of olanzapine as for schizophrenia.	FMO3 normal metabolizer genotype is not associated with clearance of olanzapine in people with Schizophrenia as compared to FMO3 intermediate metabolizer genotype.	26856397	1448631663
FMO3	rs2266780	AA	voriconazole	metabolism/PK	yes	in patients with hematopoietic stem cell transplantation and hematological malignancies.	Genotype AA is associated with increased concentrations of voriconazole as compared to genotypes AG + GG.	31932875	1451122165